Quantcast
How Far Urine Flows In A Tiny Tube Says A Lot About Your

How Far Urine Flows In A Tiny Tube Says A Lot About Your Health

Provided by Brigham Young University Innovative device detects prostate cancer, kidney disease on the spot When you flush the toilet, you may be discarding microscopic warning signs about your health. But a cunningly simple new device can...

Latest Prostate cancer Stories

2014-10-30 23:07:50

The increase in procedures to treat recurring incidences of urinary and kidney stones will drive the European stone treatment disposables markets, reports iData Research. Vancouver, BC (PRWEB) October 30, 2014 According to a new report by iData Research (http://www.idataresearch.com), the leading global authority in medical device market research, the European stone treatment device market is expected to grow to over $131 million by 2020 . The total market for stone management devices...

2014-10-30 16:29:47

Opportunities Being Developed While the Situation with the PCA3 Prostate Cancer Test is Being Resolved QUEBEC CITY, Oct. 30, 2014 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) today reports on its initiatives designed to optimize Corporate value moving forward. A number of opportunities are developing for DiagnoCure's new multi-marker prostate cancer test and its colon cancer staging test. Furthermore, even as the clinical community continues to report positive results on...

2014-10-30 16:28:46

Conference call to be held on Thursday, October 30, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash., and VANCOUVER, British Columbia, Oct. 30, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results. Q3 2014 Highlights -- The custirsen Phase 3 AFFINITY trial successfully completed patient enrollment of 635 men. AFFINITY is designed to evaluate a survival...

2014-10-30 12:30:26

While Xtandi Will Dominate the Overall Market, Emerging Hormonal Therapies Will Also Succeed in Capturing Significant Sales, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 30, 2014 /PRNewswire/ -- Decision Resources Group finds that Medivation/Astellas Pharma's Xtandi will be the sales-leading agent across the world's major markets for prostate cancer, garnering $3.4 billion in 2023. Growth in sales will be driven primarily by Xtandi's uptake as a first-line...

2014-10-30 12:29:56

HOUSTON, Oct. 30, 2014 /PRNewswire-USNewswire/ -- Improved surgical outcomes for ovarian cancer, expanded potential impact for new drugs, and a novel family outreach program to head off cancers fueled by known genetic risk mutations are among the early innovations of The University of Texas MD Anderson Cancer Center's Moon Shots Program. First-of-a-kind combination clinical trials; advanced molecular analysis to guide treatment and screening; and a focused program to gather, store, access...

2014-10-29 16:28:28

TORONTO, Oct. 29, 2014 /CNW/ - Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), today announced researchers at OICR, University Health Network (UHN) and Memorial Sloan Kettering Cancer Center (MSKCC) have identified a specific gene called PRKD1 that is mutated in the vast majority of patients with a specific type of oral salivary gland cancer. The new finding gives doctors a new target for a type of cancer that was previously...

2014-10-29 08:33:20

Procedure was accomplished using the new Edge(TM) radiosurgery system for the precise, efficient, non-invasive treatment of cancer MIAMI, Oct. 29, 2014 /PRNewswire/ -- A 71-year-old man with a tumor encroaching on his spinal cord was among the first people to receive treatment using a new Edge(TM) radiosurgery system, recently installed at Innovative Cancer Institute in Miami. A new radiosurgery platform from Varian Medical Systems (NYSE: VAR), the Edge offers doctors a fast,...

2014-10-28 23:15:52

Dr. David Schulsinger spearheads pilot study for ablation of renal cell carcinoma with SonaCare Medical’s Sonatherm® Laparoscopic Soft Tissue HIFU Surgical Ablation Device Charlotte, NC (PRWEB) October 28, 2014 SonaCare Medical, manufacturer of High Intensity Focused Ultrasound (HIFU) ablative devices, announces ongoing progress at Stony Brook University in Stony Brook, NY where Dr. David Schulsinger and his team are conducting the first North American Institutional Review Board...

2014-10-28 23:03:44

The family medical practice is now an accredited Lung Cancer Screening Center. Evans, GA (PRWEB) October 28, 2014 Center for Primary Care has been designated a Lung Cancer Screening Center by the American College of Radiology (ACR). The ACR Lung Cancer Screening Center designation is a voluntary program which recognizes facilities that have committed to practice safe, effective diagnostic care for individuals at the highest risk for lung cancer. In order to receive this elite...

2014-10-28 16:27:46

The Movember Foundation Funded Prostate Cancer Collaborative will use NexJ Connected Wellness to deliver a revolutionary program that helps men living with prostate cancer TORONTO, Oct. 28, 2014 /CNW/ - NexJ Systems Inc. (TSX: NXJ), provider of cloud-based software delivering enterprise solutions to the financial services, insurance, and healthcare industries, today announced that Prostate Cancer Canada (PCC) has selected NexJ Connected Wellness as its technology platform for...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related